|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ADD1 |
Gene summary for ADD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ADD1 | Gene ID | 118 |
| Gene name | adducin 1 | |
| Gene Alias | ADDA | |
| Cytomap | 4p16.3 | |
| Gene Type | protein-coding | GO ID | GO:0001885 | UniProtAcc | P35611 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 118 | ADD1 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.71e-09 | 5.86e-01 | -0.1954 |
| 118 | ADD1 | F007 | Human | Colorectum | FAP | 4.15e-02 | -2.05e-01 | 0.1176 |
| 118 | ADD1 | A002-C-010 | Human | Colorectum | FAP | 4.68e-03 | -2.74e-01 | 0.242 |
| 118 | ADD1 | A001-C-207 | Human | Colorectum | FAP | 8.23e-06 | -2.35e-01 | 0.1278 |
| 118 | ADD1 | A015-C-203 | Human | Colorectum | FAP | 2.34e-25 | -2.89e-01 | -0.1294 |
| 118 | ADD1 | A015-C-204 | Human | Colorectum | FAP | 3.04e-07 | -2.69e-01 | -0.0228 |
| 118 | ADD1 | A014-C-040 | Human | Colorectum | FAP | 3.71e-05 | -3.68e-01 | -0.1184 |
| 118 | ADD1 | A002-C-201 | Human | Colorectum | FAP | 2.71e-16 | -3.11e-01 | 0.0324 |
| 118 | ADD1 | A001-C-119 | Human | Colorectum | FAP | 2.81e-05 | -2.00e-01 | -0.1557 |
| 118 | ADD1 | A001-C-108 | Human | Colorectum | FAP | 2.43e-10 | -1.66e-01 | -0.0272 |
| 118 | ADD1 | A002-C-205 | Human | Colorectum | FAP | 6.83e-23 | -3.47e-01 | -0.1236 |
| 118 | ADD1 | A015-C-005 | Human | Colorectum | FAP | 9.15e-05 | -2.01e-01 | -0.0336 |
| 118 | ADD1 | A015-C-006 | Human | Colorectum | FAP | 6.32e-16 | -3.41e-01 | -0.0994 |
| 118 | ADD1 | A015-C-106 | Human | Colorectum | FAP | 1.65e-10 | -2.09e-01 | -0.0511 |
| 118 | ADD1 | A002-C-114 | Human | Colorectum | FAP | 3.36e-20 | -2.94e-01 | -0.1561 |
| 118 | ADD1 | A015-C-104 | Human | Colorectum | FAP | 3.16e-23 | -2.97e-01 | -0.1899 |
| 118 | ADD1 | A001-C-014 | Human | Colorectum | FAP | 4.14e-11 | -2.12e-01 | 0.0135 |
| 118 | ADD1 | A002-C-016 | Human | Colorectum | FAP | 3.77e-18 | -2.55e-01 | 0.0521 |
| 118 | ADD1 | A015-C-002 | Human | Colorectum | FAP | 2.69e-15 | -5.14e-01 | -0.0763 |
| 118 | ADD1 | A001-C-203 | Human | Colorectum | FAP | 2.89e-09 | -1.27e-01 | -0.0481 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00436242 | Liver | HCC | cellular protein complex disassembly | 71/7958 | 136/18723 | 1.39e-02 | 4.95e-02 | 71 |
| GO:002241119 | Oral cavity | OSCC | cellular component disassembly | 283/7305 | 443/18723 | 9.57e-27 | 3.37e-24 | 283 |
| GO:004325420 | Oral cavity | OSCC | regulation of protein-containing complex assembly | 255/7305 | 428/18723 | 2.94e-18 | 3.15e-16 | 255 |
| GO:005109820 | Oral cavity | OSCC | regulation of binding | 212/7305 | 363/18723 | 3.88e-14 | 2.15e-12 | 212 |
| GO:003298410 | Oral cavity | OSCC | protein-containing complex disassembly | 136/7305 | 224/18723 | 3.42e-11 | 1.13e-09 | 136 |
| GO:004339318 | Oral cavity | OSCC | regulation of protein binding | 121/7305 | 196/18723 | 8.92e-11 | 2.73e-09 | 121 |
| GO:190290320 | Oral cavity | OSCC | regulation of supramolecular fiber organization | 211/7305 | 383/18723 | 9.45e-11 | 2.88e-09 | 211 |
| GO:005125820 | Oral cavity | OSCC | protein polymerization | 169/7305 | 297/18723 | 2.57e-10 | 7.17e-09 | 169 |
| GO:001063918 | Oral cavity | OSCC | negative regulation of organelle organization | 190/7305 | 348/18723 | 2.12e-09 | 4.97e-08 | 190 |
| GO:005109920 | Oral cavity | OSCC | positive regulation of binding | 105/7305 | 173/18723 | 5.88e-09 | 1.26e-07 | 105 |
| GO:003227120 | Oral cavity | OSCC | regulation of protein polymerization | 134/7305 | 233/18723 | 7.20e-09 | 1.51e-07 | 134 |
| GO:000701520 | Oral cavity | OSCC | actin filament organization | 230/7305 | 442/18723 | 1.37e-08 | 2.77e-07 | 230 |
| GO:003297020 | Oral cavity | OSCC | regulation of actin filament-based process | 209/7305 | 397/18723 | 1.89e-08 | 3.72e-07 | 209 |
| GO:003253519 | Oral cavity | OSCC | regulation of cellular component size | 201/7305 | 383/18723 | 4.80e-08 | 8.88e-07 | 201 |
| GO:003295620 | Oral cavity | OSCC | regulation of actin cytoskeleton organization | 189/7305 | 358/18723 | 6.81e-08 | 1.21e-06 | 189 |
| GO:011005320 | Oral cavity | OSCC | regulation of actin filament organization | 150/7305 | 278/18723 | 2.68e-07 | 4.15e-06 | 150 |
| GO:00107209 | Oral cavity | OSCC | positive regulation of cell development | 159/7305 | 298/18723 | 3.06e-07 | 4.66e-06 | 159 |
| GO:000806417 | Oral cavity | OSCC | regulation of actin polymerization or depolymerization | 104/7305 | 188/18723 | 3.99e-06 | 4.66e-05 | 104 |
| GO:003209210 | Oral cavity | OSCC | positive regulation of protein binding | 54/7305 | 85/18723 | 4.05e-06 | 4.71e-05 | 54 |
| GO:001003820 | Oral cavity | OSCC | response to metal ion | 188/7305 | 373/18723 | 4.34e-06 | 5.00e-05 | 188 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ADD1 | SNV | Missense_Mutation | c.1276N>A | p.Asp426Asn | p.D426N | P35611 | protein_coding | deleterious(0) | possibly_damaging(0.452) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD | |
| ADD1 | SNV | Missense_Mutation | rs370911124 | c.76N>A | p.Asp26Asn | p.D26N | P35611 | protein_coding | deleterious(0) | possibly_damaging(0.761) | TCGA-AR-A0TQ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| ADD1 | SNV | Missense_Mutation | novel | c.1901N>C | p.Asp634Ala | p.D634A | P35611 | protein_coding | tolerated(0.2) | benign(0.075) | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |
| ADD1 | SNV | Missense_Mutation | rs760404515 | c.1924N>T | p.Pro642Ser | p.P642S | P35611 | protein_coding | tolerated(0.1) | probably_damaging(0.999) | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
| ADD1 | SNV | Missense_Mutation | novel | c.2224N>T | p.Pro742Ser | p.P742S | P35611 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| ADD1 | insertion | In_Frame_Ins | novel | c.1902_1903insAGGGAGGAGGAATCTAGAGAGGCAGTCTGGCTA | p.Asp634_Gln635insArgGluGluGluSerArgGluAlaValTrpLeu | p.D634_Q635insREEESREAVWL | P35611 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
| ADD1 | insertion | Nonsense_Mutation | novel | c.1925_1926insTTAAACTTCTGAAATAAAGACAGAGA | p.Pro643Ter | p.P643* | P35611 | protein_coding | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | ||
| ADD1 | deletion | Frame_Shift_Del | novel | c.533delN | p.Glu178AspfsTer15 | p.E178Dfs*15 | P35611 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| ADD1 | SNV | Missense_Mutation | novel | c.1145G>A | p.Arg382Gln | p.R382Q | P35611 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ADD1 | SNV | Missense_Mutation | c.85N>C | p.Asp29His | p.D29H | P35611 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 118 | ADD1 | KINASE | bumetanide | BUMETANIDE | 20877298 | |
| 118 | ADD1 | KINASE | hydrochlorothiazide | HYDROCHLOROTHIAZIDE | 19057513,14553962,18591455,11882573,9149697,12623934,10523341 | |
| 118 | ADD1 | KINASE | furosemide | FUROSEMIDE | 20877298,21692745 | |
| 118 | ADD1 | KINASE | torasemide | TORSEMIDE | 20877298 | |
| 118 | ADD1 | KINASE | spironolactone | SPIRONOLACTONE | 21692745 | |
| 118 | ADD1 | KINASE | diuretics | 17189961,11926892 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |